

**Stock Data**

Share Price: 1.84p  
Market Cap: 18.1m  
Shares in issue: 981.2m

**Company Profile**

Sector: Healthcare  
Ticker: SKIN  
Exchange: AIM

**Activities**

Vertically integrated test services company focused on developing and commercialising technology and products that scientifically prove the impact of skin care product claims for healthcare, life sciences, clinical research, pharmaceutical and cosmetics industries.

**Share price performance**



Source: LSE

**Past performance is not an indication of future performance.**

**Turner Pope contact details**

Turner Pope Investments (TPI)  
8 Frederick's Place  
London EC2R 8AB

Tel: 0203 657 0050  
Email: [info@turnerpope.com](mailto:info@turnerpope.com)  
Web: [www.turnerpope.com](http://www.turnerpope.com)

**Attention is drawn to the disclaimers and risk warnings at the end of this document.**

This is a non-independent marketing communication. The analyst who has prepared this report is aware that TPI has a relationship with the company covered in this report. Accordingly, it has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

**TPI acts as joint broker to Integumen PLC.**

Retail clients (as defined by the rules of the FCA) must not rely on this document.

**Barry Gibb** Research analyst  
Tel: 0203 657 0061  
[Barry.Gibb@turnerpope.com](mailto:Barry.Gibb@turnerpope.com)

# Integumen plc

**Integumen has announced successful results from its participation in a water research project that utilises Rinocloud Artificial Intelligence ('AI'). The three-year development Remote Automated Water Test research project ('RAWTest'), comprising a consortium partly funded by the Irish Environmental Protection Agency (EPA), anticipates increasingly global dependence on recycling and recovery of water supplies. As such, a regular, rapid and accurate means of wireless monitoring is urgently needed to ensure they are fit for human consumption. Rinocloud AI has demonstrated its ability to deliver exactly this, by remotely detecting E.coli contaminated water with 99.3% accuracy in just 3.37 seconds, thereby offering significant potential to improve global healthcare.**

The RAWTest project consortium is comprised of the Irish Environmental Protection Agency (EPA), Cork Institute of Technology's (CIT) Centre for Advanced Photonics & Process Analysis (Cappa Group), the CIT Nimbus embedded systems research institute and the AI team from Integumen's Rinocloud subsidiary.

Rinocloud's AI platform was used to test water samples from a fully autonomous data buoy deployed on the Inniscarra Water Reservoir in Cork, Ireland for E.coli, a bacterium that can cause illness in humans, including diarrhoea, abdominal pain, fever and sometimes vomiting. Rinocloud's rapid positive detection compares to the current standard test detection time of between 5-7 days, according to Integumen.

The lack of freshwater resources to meet consumer demand now affects every continent and was listed in 2019 by the World Economic Forum as one of the largest global risks in terms of potential impact over the next decade. The deployment of wireless RAWTest buoys in water treatment plants would be a world first and have a positive impact on water consumer service metrics, reducing the average length of time water would be shut off in the event of contamination, reduced 'boil-water' notices and reduce time required to restore supply, as well as biological quality.

There are multiple commercial opportunities for RAWTest. With 20 known species of listeria bacterium, for example, all public buildings including hospitals, hotels, conference halls and senior citizen nursing homes are at risk of contamination. Remote detection and analysis of malaria in blood in third world-countries is another obvious need, as well as for military use. Adoption by in-line milking machines for detection of mastitis in individual cows, would also enable instant action to eliminate contamination from dairy herd milk collection, while an early warning system in fermentation processes for ethanol, alcohol and wine producers at risk of bacterial hazard would improve consumer safety, stability and longevity.

**Today's announcement highlights further significant commercial potential for Rinodrive's data aggregation, refining and AI analysis open-source eco-system. It is designed to offer service providers valuable insights in support of clinical, operational and financial decisions in healthcare services, third-level education, government departments and the financial sector. Excluding additional longer-term revenues that might be expected to accrue from such new opportunities, the Company has also recently provided investors with guidance of £4m revenues for its year to end-2020E, based on current visibility from existing data-as-a-service to skincare R&D framework multi-year contracts, while also confirming that RinoDrive had moved into monthly profitability at the half-year stage.**

**THIS DOCUMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA OR AUSTRALIA.**

### **Conflicts**

This is a non-independent marketing communication under the rules of the Financial Conduct Authority ("FCA"). The analyst who has prepared this report is aware that Turner Pope Investments (TPI) Limited ("TPI") has a relationship with the company covered in this report. Accordingly, the report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing by TPI or its clients ahead of the dissemination of investment research.

TPI manages its conflicts in accordance with its conflict management policy. For example, TPI may provide services (including corporate finance advice) where the flow of information is restricted by a Chinese wall. Accordingly, information may be available to TPI that is not reflected in this document. TPI may have acted upon or used research recommendations before they have been published.

### **Risk Warnings**

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Any opinions expressed in this document are those of TPI's research analyst. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price.

The value of securities, particularly those of smaller companies, can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of smaller company securities may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results.

AIM is a market designed primarily for emerging or smaller companies and the rules of this market are less demanding than those of the Official List of the UK Listing Authority; consequently AIM investments may not be suitable for some investors. Liquidity may be lower and hence some investments may be harder to realise.

### **Specific disclaimers**

TPI acts as joint broker to Integumen plc ("Integumen") which is listed on the AIM Market of the London Stock Exchange ("AIM"). TPI's private and institutional clients may hold, subscribe for or buy or sell Integumen's securities.

This document has been produced by TPI independently of Integumen. Opinions and estimates in this document are entirely those of TPI as part of its internal research activity. TPI has no authority whatsoever to make any representation or warranty on behalf of Integumen.

**General disclaimers**

This document, which presents the views of TPI's research analyst, cannot be regarded as "investment research" in accordance with the FCA definition. The contents are based upon sources of information believed to be reliable but no warranty or representation, express or implied, is given as to their accuracy or completeness. Any opinion reflects TPI's judgement at the date of publication and neither TPI nor any of its directors or employees accepts any responsibility in respect of the information or recommendations contained herein which, moreover, are subject to change without notice. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price. TPI does not undertake to provide updates to any opinions or views expressed in this document. TPI accepts no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by applicable law).

The information in this document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

This document is approved and issued by TPI for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to professional clients, as defined by Directive 2004/39/EC as set out in the rules of the Financial Conduct Authority. This document may not be published, distributed or transmitted to persons in the United States of America, Japan, Canada or Australia. This document may not be copied or reproduced or re-distributed to any other person or organisation, in whole or in part, without TPI's prior written consent.

Copyright © 2019 Turner Pope Investments (TPI) Limited, all rights reserved.